Drug Profile
Bezafibrate extended release - Beijing CoSci Med Tech
Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Beijing CoSci Med-Tech
- Class Antihyperlipidaemics; Benzamides; Fibric acid derivatives; Phenylbutyrates; Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Hyperlipidaemia
Most Recent Events
- 29 Jul 2016 Chemical structure information added
- 25 Jul 2016 Investigation in Hyperlipidaemia in China (PO)